MDDX Launches New Software To Empower Biomedical Scientists To Scale Their Studies Globally

Share Article

New “MulticenterTM Platform” Democratizes Scientific Research Tools

MDDX, a provider of biomedical research software and services for pharmaceutical, biotechnology and medical device industries today announced the release of their MulticenterTM Platform. This unique suite of applications and services provides biotech and academic researchers with the same technological advantages that multinational pharmaceutical companies and CROs employ.

The MDDX Multicenter TM Platform allows researchers to find and recruit research sites, train staff members, screen patients, collect data and track the results in real-time. Scientists can choose to use individual applications or utilize the entire suite as a turnkey comprehensive solution. All server and security measures are included in this fully hosted solution. To ensure 21 CFR compliance, all records, transactions, and logs are stored in an automatic audit trail system called DataVault.

“We are extremely proud of the impact the MulticenterTM Suite has already had on disease discovery. In over a dozen studies, researchers have been able to immediately scale their studies by adding more sites, building and deploying their own eCRFs, and transferring large medical images around the world - all for a fraction of the cost of what a CRO would charge,” said Dan Gebow, CEO of MDDX.

MDDX supports all the applications with optional services such as custom data visualizations, site management, and imaging core lab interpretation.

About MDDX

MDDX, LLC ( provides research services and medical informatics to accelerate biomedical research and patient care. Founded by scientists, physicians and software engineers, MDDX currently assists in research studies in over 20 countries with focuses ranging from coronary artery disease to traumatic brain injury. MDDX is based in San Francisco, CA.

David Leflang
Communications Director
Phone +1 800 441 6339
dleflang at


Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Leflang
(800) 922-6816
Email >